Completed

Recombinant Human CD4 Immunoglobulin G for HIV-Associated Immune Thrombocytopenic Purpura

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

CD4-IgG

Drug
Who is being recruted

Blood-Borne Infections+28

+ Urogenital Diseases

+ Genital Diseases

Over 18 Years
+20 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1
Interventional
See protocol details

Summary

Principal SponsorGenentech, Inc.
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

This clinical trial focuses on evaluating the effectiveness of a treatment called recombinant human CD4 Immunoglobulin G (CD4-IgG) in managing HIV-associated immune thrombocytopenic purpura. This condition is a disorder where the immune system destroys platelets, which are blood cells responsible for clotting. The study is designed for patients with all levels of HIV infection. The importance of this study lies in its potential to find a new treatment method for this specific complication associated with HIV, which could significantly improve patient care and quality of life.

Principal SponsorGenentech, Inc.
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Blood-Borne InfectionsUrogenital DiseasesGenital DiseasesCytopeniaAutoimmune DiseasesBlood Coagulation DisordersBlood Platelet DisordersCommunicable DiseasesHematologic DiseasesHemic and Lymphatic DiseasesHemorrhageHemorrhagic DisordersImmunologic Deficiency SyndromesImmune System DiseasesInfectionsPathologic ProcessesPurpuraPurpura, ThrombocytopenicRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted DiseasesSigns and SymptomsSkin ManifestationsPathological Conditions, Signs and SymptomsThrombocytopeniaVirus DiseasesSexually Transmitted Diseases, ViralLentivirus InfectionsThrombotic MicroangiopathiesHIV InfectionsPurpura, Thrombocytopenic, Idiopathic

Criteria

10 inclusion criteria required to participate
Zidovudine (AZT) at a constant dose for the 12 weeks of treatment, except if AZT-related toxicity is observed.

Dapsone at a constant dose level and only as a prophylaxis for Pneumocystis carinii pneumonia (PCP).

Dapsone at a constant dose for more than 2 weeks prior to study entry.

Zidovudine at a constant dose for 4 weeks prior to study entry.

Show More Criteria

10 exclusion criteria prevent from participating
Ganciclovir (DHPG). Pyrimethamine. Clindamycin. Sulfadiazine. Folinic acid. Prednisone. Intravenous gamma globulin. Intravenous acyclovir. Interferon. Systemic corticosteroids. Non-steroidal anti-inflammatory drugs (NSAIDs). Known immunomodulatory agents. Dideoxycytosine. Dideoxyinosine. Nucleoside analogs (with the exception of zidovudine or topical acyclovir). Any experimental therapy.

Chemotherapy. Immunomodulatory agents. Any experimental therapy. Radiation therapy. Any experimental therapy.

Tumor-associated edema.

Conditions requiring excluded concomitant medications.

Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

San Francisco Gen Hosp

San Francisco, United StatesOpen San Francisco Gen Hosp in Google Maps
CompletedOne Study Center